Views & Analysis NICE plans to charge for appraisals – but pharma wants refor... Will NICE introduce fees for pharma companies' TAs from next year?
Views & Analysis PPRS and devolution: over £60m to Greater Manchester? Does the local NHS in England get its fair share of PPRS money?
Views & Analysis Meeting the challenges of rare disease treatment adherence HCPs, pharma and patients can pool their experience to develop effective, tailored support.
Views & Analysis Fighting diminishing HCP access Predictive sales analytics can help pharma reps make limited time with healthcare professionals count.
Views & Analysis Saving the jewel in the crown of ‘UKplc’: Brexit's impact on... Pharma must embrace the opportunity to shape the UK’s political agenda in its favour.
Partner Content Partner Content The new CDF - Navigating Cancer Drug Access in England On July 29th 2016, the new process in England for cancer drugs seeking license went live - changing both the shape and potential requirements of the submissions process.
News 23andMe study explains variable results with obesity drugs Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
